Shanghai-listed North China Pharmaceutical Co. (600812.SH) said on Tuesday that its Drug Master File (DMF) of recombining human albumin had received approval from US Food and Drug Administration, and the relevant products are given access to the international market.
North China Pharmaceutical saw a 10 percent limit-up on Tuesday to end at 8.22 yuan per share.


Latest comments